LEC-derived immune-inhibitory ligands dampen effector T cell function in cancer (119, 120), neuroinflammation (121), and infection (69), and we confirmed the expression of 2 exemplar molecular candidates, PVR and LGALS9, at both the transcript and protein level. The gene discussed is LGALS9; the disease is cancer.